References
- Tate JE, Burton AH, Boschi-Pinto C, Parashar UD. Global, regional, and national estimates of rotavirus mortality in children < 5 years of age, 2000-2013. Clin Infect Dis. 2016;62:S96–S105.
- Clark A, van Zandvoort K, Flasche S, Sanderson C, Bines J, Tate J, Parashar U, Jit M. Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials. Lancet Infect Dis. 2019;19:717–27. doi:10.1016/S1473-3099(19)30126-4.
- Rogawski ET, Platts-Mills JA, Colgate ER, Haque R, Zaman K, Petri WA, Kirkpatrick BD. Quantifying the impact of natural immunity on rotavirus vaccine efficacy estimates: a clinical trial in Dhaka, Bangladeshh (PROVIDE) and a simulation study. J Infect Dis. 2018;217:861–68. doi:10.1093/infdis/jix668.
- Smith PG, Rogriguez LC, Fine PE. Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int J Epidemiol. 1984;13:87–93. doi:10.1093/ije/13.1.87.
- Mohan VR, Karthikeyan R, Babji S, McGrath M, Shrestha S, Shrestha J, Mdumah E, Amour C, Samie A, Emanuel N, et al. Rotavirus infection and disease in a multisite birth cohort: results from the MAL-ED Study. J Infect Dis. 2017;216:305–16. doi:10.1093/infdis/jix199.
- Durham LK, Longini IM, Halloran ME, Clemens JD, Nizam A, Rao M. Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines. Amer J Epidemiol. 1998;147:948–59. doi:10.1093/oxfordjournals.aje.a009385.
- Schoenfeld D. Partial residuals for the proportional hazard regression model. Biometrika. 1982;69:239–41. doi:10.1093/biomet/69.1.239.
- Tian L, Zucker D, Wei LJ. On the Cox model with time-varying regression coefficients. J Amer Statist Assoc. 2005;100:172–83. doi:10.1198/016214504000000845.
- Klein JP, Moeschberger ML. Survival analysis: techniques for censored and trancated data. New York: Springer Science & Business Media; 2006.